On March 13, 2023 AnHeart Therapeutics ("AnHeart"), a clinical-stage global biopharmaceutical company committed to developing novel precision oncology therapeutics, reported acceptance of an oral presentation at the European Lung Cancer Congress (ELCC) 2023, held in Copenhagen, Denmark and virtually, March 29 – April 1 (Press release, AnHeart Therapeutics, MAR 13, 2023, View Source [SID1234628608]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
This oral presentation at ELCC 2023 will provide updated efficacy and safety data of taletrectinib regional Phase 2 study (TRUST-I, NCT04395677) with about 1.5-year follow-up in patients. Taletrectinib is a potent, next-generation, CNS-active, ROS1 tyrosine kinase inhibitor (TKI). In previous reports from the TRUST-I study, taletrectinib showed meaningful clinical efficacy and favorable safety profiles in patients with ROS1+ NSCLC (n=109) regardless of crizotinib pretreatment status.
Separately, a global taletrectinib Phase 2 clinical trial (TRUST-II, NCT04919811) is ongoing and actively enrolling patients in North America, Europe and Asia.
The details of the oral presentation are as follows:
Title: Updated Efficacy and Safety of Taletrectinib in Patients with ROS1+ Non-Small Cell Lung Cancer (NSCLC)
Presentation Session Number: 14MO
Presenter: Dr. Wei Li, Shanghai Pulmonary Hospital and Thoracic Cancer Institute, Tongji University School of Medicine, Shanghai, China
Date: Friday March 31, 2023
Location: Auditorium 1, Bella Center Copenhagen, Copenhagen, Denmark
The ELCC 2023 Program can be accessed online at: View Source